Eris Lifesciences Limited (ERIS)

Loading page…

Eris Lifesciences Limited (ERIS) · mywealthgrid

About

Eris Lifesciences operates in pharmaceuticals with ₹18.8k Cr market cap and 35.79% operating margin, positioning it as a mid-tier player. The company operates through a consolidated group structure—consolidated revenues (₹873 Cr in Jun 2026) roughly double standalone operations (₹443.99 Cr)—suggesting growth through acquisitions.

Face value: ₹1

Market cap

₹16,491 Cr

P/E

25.6×

P/B

4.2×

Dividend yield

0.6%

ROE

18.3%

ROCE

15.5%

Debt / equity

0.59

OPM

35.8%

EPS (TTM)

₹46.5

Book value

₹281.8

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Profitability highly volatile—EPS ranges from -0.63 to 20.6 across recent quarters; verify if volatility reflects seasonality, project dependency, or operational instability
Operating margins swing widely from 7.85% to 45.64%; verify if divergence stems from product or geographic mix shifts or execution inconsistency
Stock declined 19.83% over one year despite 18.34% ROE; verify what market concerns about execution or growth sustainability underlie the decline
Standalone business significantly underperforms consolidated (Mar 2026 standalone -₹8.6 Cr profit vs consolidated ₹279.1 Cr); clarify if this reflects consolidation accounting or operational weakness

Generated analysis · source review pending

Growth drivers

Consolidated revenues roughly double standalone (Jun 2026: ₹873 Cr vs ₹443.99 Cr), indicating scale through acquisitions or consolidation; verify M&A pipeline and integration roadmap
Operating margins at 35.79% and reaching 45.64% in strong quarters; verify if product mix improvements or execution consistency can sustain margins at scale
Dividend history with regular payouts spanning 2020–2026 indicates cash generation strength; verify capital allocation plans for organic growth investments

Generated analysis · source review pending

2,284 historical price candles were omitted because the exchange source has not been verified.

₹1,189.8-2.4%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 35.8%
+Revenue CAGR of 20.9% over the last 5 years

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

60/100

Business quality: 57
Growth: 66
Valuation: 58

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	750	856	982	1,074	1,212	1,347	1,685	2,009	2,894	3,129
COGS	105	134	154	172	238	259	352	380	714	796
Gross profit	645	722	828	903	974	1,089	1,333	1,629	2,180	2,334
	—	400	484	534	543	604	796	954	1,162	1,214
	—	322	345	368	431	485	537	675	1,017	1,120
OPM %	—	37.6%	35.1%	34.3%	35.5%	36%	31.9%	33.6%	35.2%	35.8%
Depreciation	23	26	36	50	43	65	117	183	315	280
Interest	1	11	23	2	2	4	26	85	231	193
	25	26	32	15	9	26	11	24	18	-9
Profit before tax	270	312	317	331	395	442	405	431	489	639
Tax	24	17	26	35	39	36	30	34	114	-9
Tax %	8.8%	5.5%	8.3%	10.5%	10%	8.2%	7.5%	7.9%	23.4%	-1.4%
	247	295	291	297	355	406	374	397	375	648
PAT margin %	32.9%	34.5%	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%	13%	20.7%
EPS (₹)	—	21.4	21.2	21.6	26.2	29.9	28.1	28.8	25.9	45.3
EPS adjusted (₹)	18	21.4	21.2	21.8	26.2	29.9	28.1	28.8	25.8	44.7
	—	0%	0%	13.3%	21%	20.1%	26.2%	0%	28.4%	—
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	0	14	14	14	14	14	14	14	14	14	14
Reserves	296	522	848	1,137	1,283	1,563	1,895	2,182	2,573	2,841	3,889
Minority interest	—	—	25	18	—	—	—	25	636	417	—
	0	0	274	0	0	0	45	830	2,735	2,478	2,310
	97	101	300	385	256	258	319	617	1,092	1,283	1,153
Total equity & liabilities	393	637	1,460	1,554	1,552	1,835	2,272	3,667	7,049	7,033	7,366
	71	92	771	761	869	854	918	2,568	4,328	5,306	5,188
CWIP	—	—	1	1	—	0	24	21	19	67	171
Investments	190	269	365	356	78	294	520	37	16	67	62
	132	277	323	437	606	687	810	1,041	2,687	1,593	1,945
Total assets	393	637	1,460	1,554	1,552	1,835	2,272	3,667	7,049	7,033	7,366

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	84.4%	84%	80.3%	80.8%	79.1%	81.1%	75.3%	74.6%
EBITDA margin %	35.1%	34.3%	35.5%	36%	31.9%	33.6%	35.2%	35.8%
EBIT margin %	31.4%	29.6%	32%	31.2%	24.9%	24.5%	24.3%	26.9%
PAT margin %	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%	13%	20.7%
Working capital
Receivable days	31	53	42	44	63	77	58	79
Inventory days	196	148	145	166	136	182	171	200
Payable days	—	—	157	166	129	258	170	151
NWC days	—	—	30	44	70	0	59	129
Leverage
Current ratio	1.9	2.91	2.8	3.14	1.73	0.91	0.91	0.74
Debt to EBITDA	0	0	0	0.09	1.55	4.05	2.44	2.06
Debt to equity	0	0	0	0.02	0.38	1.06	0.87	0.59
Interest coverage	14.9	154.4	220.2	107.6	16.5	6.1	3.1	4.4
Asset turnover	0.63	0.69	0.66	0.59	0.46	0.29	0.41	0.42
Return ratios
Return on assets %	18.7%	19.1%	19.4%	17.9%	10.2%	5.6%	5.3%	8.8%
Return on capital employed %	27.4%	25.3%	25.9%	23.9%	16.3%	13.3%	14.2%	15.5%
Return on equity %	25.3%	22.9%	22.5%	21.3%	17%	15.4%	13.1%	16.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	54.91%	54.9%	54.9%	54.88%	54.87%	54.86%	54.85%	54.83%	54.85%	54.85%	53.92%	54.14%
	13.2%	13.14%	14.27%	14.59%	8.01%	8.35%	8.43%	8.4%	7.21%	6.85%	6.39%	5.75%
	14.53%	14.56%	15.63%	16.23%	18.64%	18.06%	18.07%	18.17%	19.36%	20.32%	20.35%	20.72%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	17.36%	17.4%	15.2%	14.3%	18.48%	18.73%	18.65%	18.6%	18.58%	17.98%	19.34%	19.39%
No. of shareholders	—	—	—	—	—	—	—	—	59,438	54,713	51,656	50,798

Promoter holding down 0.77 percentage points since Sep 2023.

26 deals · 29 Apr 2022 – 3 Oct 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
3 Oct 2024	MOTILAL OSWAL FINANCIAL SERVICES LIMITED	Bulk	NSE	Buy	20,79,000	₹1,350.18	₹280.70 Cr
3 Oct 2024	RAKESH SHAH	Bulk	NSE	Sell	20,00,000	₹1,350.00	₹270.00 Cr
22 Aug 2024	INFINITY PARTNERS	Block	NSE	Buy	98,86,882	₹1,201.00	₹1,187.41 Cr
22 Aug 2024	EMERALD INVESTMENTS LIMITED	Block	NSE	Sell	98,86,882	₹1,201.00	₹1,187.41 Cr
22 Aug 2024	INFINITY PARTNERS	Bulk	NSE	Buy	98,86,882	₹1,201.00	₹1,187.41 Cr
22 Aug 2024	EMERALD INVESTMENTS LIMITED	Bulk	NSE	Sell	98,86,882	₹1,201.00	₹1,187.41 Cr
15 Jul 2024	RAKESH SHAH	Bulk	NSE	Sell	20,00,000	₹1,000.12	₹200.02 Cr
15 Jul 2024	FRANKLIN TEMPLETON MUTUAL FUND	Bulk	NSE	Buy	10,94,201	₹1,000.04	₹109.42 Cr
31 Jan 2024	BHIKHALAL CHIMANLAL SHAH	Bulk	BSE	Sell	12,80,000	₹913.09	₹116.88 Cr
31 Jan 2024	BHIKHALAL CHIMANLAL SHAH	Bulk	NSE	Sell	8,20,000	₹912.50	₹74.83 Cr

1–10 of 26

1 / 3

Mr. AMIT INDUBHUSHAN BAKSHIExecutive Director-Chairperson-MD
Sachin ShahChief Financial Officer
Mr. KAUSHAL KAMLESH SHAHExecutive Director
Mr. KRISHNAKUMAR VAIDYANATHANExecutive Director
Mr. INDERJEET SINGH NEGIExecutive Director
Ms. KALPANA VASANTRAI UNADKATNon-Executive - Independent Director
Mr. SUJESH VASUDEVANNon-Executive - Independent Director
Mr. PRASHANT GUPTANon-Executive - Independent Director
Mr. VINEET VARMANon-Executive - Independent Director
Milind TalegaonkarCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 12 fund houses

Held by these funds

5.42%

of the company's equity

All mutual funds

18.88%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

42 schemes · 12 fund houses

		Shares
Franklin India Small Cap Fund (Formerly known as Franklin India Smaller Companies Fund) ^	Franklin Templeton Mutual Fund	22.34 L	289.77	1.97%	1.612%	-0
Franklin India Flexi Cap Fund ( Formerly known as Franklin India Equity Fund) ^NEW	Franklin Templeton Mutual Fund	14.1 L	182.94	0.94%	1.018%	—
Small Cap Fund	DSP Mutual Fund	12.3 L	159.56	0.74%	0.887%	-0
Franklin India Multi Cap Fund	Franklin Templeton Mutual Fund	4.55 L	59.07	1.12%	0.329%	-3,963
SMALL CAP FUND	Bank of India Mutual Fund	3.36 L	43.64	1.32%	0.243%	-0
Multi Cap FUND	Bank of India Mutual Fund	2.27 L	29.45	2.21%	0.164%	-0
Healthcare Fund	DSP Mutual Fund	2.26 L	29.3	0.76%	0.163%	-0
Aggressive Hybrid FundNEW	Bank of India Mutual Fund	2.03 L	26.31	1.28%	0.146%	—

1–8 of 42

1 / 6

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

as attached8 May 2026

Investor Presentation and earnings call

May 2026Transcript AI Summary PPTREC
Feb 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

6

Interim dividend29 May 2026 · ex-date₹7.21
Interim dividend13 Feb 2025 · ex-date₹7.35
Interim dividend11 Aug 2022 · ex-date₹7.35
Interim dividend5 Aug 2021 · ex-date₹6.01
Interim dividend13 Aug 2020 · ex-date₹5.5
Interim dividend19 Mar 2020 · ex-date₹2.87

1

Board meeting to consider results29 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

99 announcementsExport CSV

28 Sept 2026, 5:35 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

22 Sept 2026, 4:49 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment

Allotment of Equity Shares PDF

21 Sept 2026, 9:11 amCompany Update

Appointment Of Mr. Akhil Awasthi As An Additional Director (Non-Executive, Independent) Of The Company

General PDF

11 Sept 2026, 4:12 pmCompany Update

Announcement under Regulation 30 (LODR)-Resignation of Director

Resignation of Director PDF

10 Sept 2026, 5:20 pmCompany Update

Rumour Verification - Regulation 30(11)

General PDF

9 Sept 2026, 5:27 pmCompany Update

Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Term Loan From Axis Bank

General PDF

7 Sept 2026, 12:25 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

3 Sept 2026, 12:17 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
28 Sept 2026, 5:35 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
22 Sept 2026, 4:49 pm	Company Update Allotment of Equity Shares	Announcement under Regulation 30 (LODR)-Allotment	PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	84.4%	84%	80.3%	80.8%	79.1%	81.1%	75.3%	74.6%
EBITDA margin %	35.1%	34.3%	35.5%	36%	31.9%	33.6%	35.2%	35.8%
EBIT margin %	31.4%	29.6%	32%	31.2%	24.9%	24.5%	24.3%	26.9%
PAT margin %	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%	13%	20.7%
Working capital
Receivable days	31	53	42	44	63	77	58	79
Inventory days	196	148	145	166	136	182	171	200
Payable days	—	—	157	166	129	258	170	151
NWC days	—	—	30	44	70	0	59	129
Leverage
Current ratio	1.9	2.91	2.8	3.14	1.73	0.91	0.91	0.74
Debt to EBITDA	0	0	0	0.09	1.55	4.05	2.44	2.06
Debt to equity	0	0	0	0.02	0.38	1.06	0.87	0.59
Interest coverage	14.9	154.4	220.2	107.6	16.5	6.1	3.1	4.4
Asset turnover	0.63	0.69	0.66	0.59	0.46	0.29	0.41	0.42
Return ratios
Return on assets %	18.7%	19.1%	19.4%	17.9%	10.2%	5.6%	5.3%	8.8%
Return on capital employed %	27.4%	25.3%	25.9%	23.9%	16.3%	13.3%	14.2%	15.5%
Return on equity %	25.3%	22.9%	22.5%	21.3%	17%	15.4%	13.1%	16.6%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	131	200	235	223	271	375	378	292	486	1,065	538
	-44	-184	-590	-5	123	-323	-320	-975	-1,828	-80	-369
	-84	-24	363	-221	-335	-82	-45	688	1,380	-881	-314
Net cash flow	4	-8	8	-3	60	-30	14	5	38	104	-145
Free cash flow	108	150	210	185	120	350	257	-550	357	910	241
CFO / Operating profit %	—	—	72.9%	64.7%	73.6%	87.2%	78%	54.4%	72%	104.7%	48%

Eris Lifesciences Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

6

1

Announcements

Not in the F&O segment

6

1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Eris Lifesciences Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends6

Board meetings1

Announcements

Not in the F&O segment

Dividends6

Board meetings1

Ratio timeline

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

6

1

6

1